Payment overview · 2025
General Payments
$1,522.21
79 reported records · 22 companies
Healthcare provider profile · identity verified
Matthew D'Onofrio, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBURG, PA · NPI 1285607705
Verified facts
What the public records show
CMS Open Payments records show Matthew D'Onofrio, MD received $1,522.21 in general payments during 2025 across 79 reported records.
PFIZER INC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Entresto, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 457 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 457 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $229.15 | 15.1% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $192.68 | 12.7% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.61 | 10.8% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $162.94 | 10.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $133.89 | 8.8% | 8 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $61.42 | 4.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.56 | 3.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.75 | 3.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.56 | 3.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.21 | 3.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $50.00 | 3.3% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.58 | 2.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $36.39 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.17 | 2.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.91 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.09 | 2.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.84 | 1.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $25.88 | 1.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.78 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.53 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.71 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.56 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,522.21 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $189.71 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $147.90 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $108.34 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $104.69 | 6 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $100.41 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $97.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.40 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $85.02 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.25 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.18 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $62.53 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $61.42 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.56 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $50.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.44 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.44 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $36.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.91 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.84 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 130 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 457 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 199 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 198 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 176 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 145 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
174 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
199 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
198 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
457 | 79 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
130 | 130 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
145 | 89 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
198 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
121 | 18 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
176 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
457 | 79 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1055 | 254 |
| Levothyroxine Sodium | Levothyroxine Sodium | 815 | 179 |
| Simvastatin | Simvastatin | 747 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 646 | 151 |
| Lisinopril | Lisinopril | 613 | 138 |
| Metoprolol Tartrate | Metoprolol Tartrate | 500 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 460 | 118 |
| Eliquis | Apixaban | 457 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 434 | 109 |
| Metformin Hcl | Metformin Hcl | 427 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 82 |
| Losartan Potassium | Losartan Potassium | 363 | 87 |
| Omeprazole | Omeprazole | 327 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 323 | 80 |
| Potassium Chloride | Potassium Chloride | 319 | 62 |
| Irbesartan | Irbesartan | 284 | 70 |
| Gabapentin | Gabapentin | 264 | 56 |
| Furosemide | Furosemide | 262 | 59 |
| Allopurinol | Allopurinol | 243 | 61 |
| Ramipril | Ramipril | 221 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 45 |
| Farxiga | Dapagliflozin Propanediol | 199 | 33 |
| Jardiance | Empagliflozin | 198 | 40 |
| Sertraline Hcl | Sertraline Hcl | 189 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 178 | 27 |
| Ozempic | Semaglutide | 176 | 29 |
| Donepezil Hcl | Donepezil Hcl | 175 | 28 |
| Synthroid | Levothyroxine Sodium | 174 | 41 |
| Warfarin Sodium | Warfarin Sodium | 174 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 51 |
| Atenolol | Atenolol | 167 | 40 |
| Lorazepam | Lorazepam | 157 | 46 |
| Tramadol Hcl | Tramadol Hcl | 155 | 36 |
| Ezetimibe | Ezetimibe | 147 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 145 | 89 |
| Finasteride | Finasteride | 135 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 130 | 130 |
| Metformin Hcl Er | Metformin Hcl | 130 | 29 |
| Spironolactone | Spironolactone | 124 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 34 |
| Trulicity | Dulaglutide | 121 | 18 |
| Xarelto | Rivaroxaban | 120 | 22 |
| Celecoxib | Celecoxib | 118 | 22 |
| Trazodone Hcl | Trazodone Hcl | 118 | 21 |
| Tradjenta | Linagliptin | 116 | 23 |
| Alprazolam | Alprazolam | 115 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 23 |
| Valsartan | Valsartan | 105 | 30 |
| Alendronate Sodium | Alendronate Sodium | 104 | 26 |
| Mirtazapine | Mirtazapine | 104 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 27 |
| Enalapril Maleate | Enalapril Maleate | 93 | 20 |
| Clonazepam | Clonazepam | 89 | 21 |
| Glimepiride | Glimepiride | 89 | 23 |
| Benazepril Hcl | Benazepril Hcl | 86 | 19 |
| Glipizide | Glipizide | 84 | 16 |
| Montelukast Sodium | Montelukast Sodium | 83 | 23 |
| Meloxicam | Meloxicam | 82 | 25 |
| Carvedilol | Carvedilol | 80 | 16 |
| Repatha Sureclick | Evolocumab | 76 | suppressed |
| Bumetanide | Bumetanide | 75 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 28 |
| Cephalexin | Cephalexin | 68 | 55 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 16 |
| Myrbetriq | Mirabegron | 66 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 22 |
| Digoxin | Digoxin | 60 | suppressed |
| Fenofibrate | Fenofibrate | 58 | 15 |
| Amoxicillin | Amoxicillin | 57 | 43 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 12 |
| Clonidine Hcl | Clonidine Hcl | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 11 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 13 |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 38 | 38 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Famotidine | Famotidine | 38 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 25 |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Jantoven | Warfarin Sodium | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 29 |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 24 |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 13 |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Asmanex | Mometasone Furoate | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Prednisone | Prednisone | 25 | 16 |
| Repaglinide | Repaglinide | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 20 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Naproxen | Naproxen | 19 | 12 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,522.21 · 79 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAMZYOS, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, INSPIRE, JARDIANCE, KISUNLA, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, WATCHMAN, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error